|
| Monday, January 22, 2018 |
|
|
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib) |
| Eisai Co., Ltd. announced today that the results of an analysis of a Phase III trial of its in-house discovered and developed anticancer agent lenvatinib mesylate versus sorafenib. more info >> |
|
| Saturday, January 20, 2018 |
|
|
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan |
| Eisai's subsidiary for gastrointestinal disease area EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd today announced that EA Pharma has obtained new drug approval for bile acid transporter inhibitor "GOOFICE 5mg Tablet" for chronic constipation (excluding structural disease-induced constipation) in Japan. more info >> |
|
| Friday, January 19, 2018 |
|
|
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan |
| Sato Pharmaceutical Co., Ltd. obtained marketing and manufacturing approval for the oral antifungal agent NAILIN Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (fosravuconazole) for the treatment of onychomycosis in Japan on January 19, 2018. more info >> |
|
|
Eisai Enters into Licensing Agreement with Adlai Nortye for Potential Anticancer Agent E7046 |
| Eisai Co., Ltd. announced today that it has entered into a licensing agreement granting exclusive rights concerning the research, development, manufacture and marketing of Eisai's in-house discovered potential anticancer agent E7046. more info >> |
|
| Thursday, January 18, 2018 |
|
|
Eisai: Patent Infringement Litigation for Antiemetic Agent ALOXI in the United States |
| Eisai has announced today that the United States Court of Appeals for the Federal Circuit, in the patent infringement lawsuit for antiemetic agent ALOXI (palonosetron hydrochloride) injection has denied Helsinn's petition for rehearing en banc. more info >> |
|
| Thursday, January 11, 2018 |
|
|
Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. has completed construction of a new oral solid dose production facility and an administration building at the site of its new Suzhou plant located within the Suzhou Industrial Park. more info >> |
|
| Tuesday, January 9, 2018 |
|
|
Biogen and Eisai Commence Co-Promotion of Multiple Sclerosis Treatments in Japan |
| Eisai Co., Ltd. and Biogen Japan Ltd. announced that the companies have commenced co-promotion of Biogen Japan's multiple sclerosis treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of today. more info >> |
|
|
Eisai and Merck & Co. Receive Breakthrough Therapy Designation from U.S. FDA for LENVIMA and KEYTRUDA |
| The LENVIMA and KEYTRUDA combination therapy is being jointly developed by Eisai and MSD. This is the second Breakthrough Therapy Designation for LENVIMA and the twelfth Breakthrough Therapy Designation granted to KEYTRUDA. more info >> |
|
| Wednesday, December 27, 2017 |
|
|
Eisai: Anticancer Agent Lenvatinib Designated for Priority Review and Approval by CFDA for Hepatocellular Carcinoma |
| Eisai Co., Ltd. announced that its in-house discovered and developed anticancer agent lenvatinib mesylate for use in the treatment of HCC, which was submitted for approval in China in October 2017, has been designated for Priority Review and Approval by CFDA due to lenvatinib's significant clinical benefit compared to existing treatments. more info >> |
|
| Friday, December 22, 2017 |
|
|
Eisai: Adaptive Phase II Study of BAN2401 In Early Alzheimer's Disease Continues Toward 18-Month Endpoint |
| Eisai Co., Ltd. and Biogen Inc. announced today that an Independent Data Monitoring Committee has determined that BAN2401, an anti-amyloid beta protofibril antibody, did not meet the criteria for success based on a Bayesian analysis at 12 months as the primary endpoint in an 856-patient Phase II clinical study (Study 201). more info >> |
|
|
|
